You have 10 free articles left this month. Get your freeBasic subscription now and gain instant access to more.

Slovenian drug maker Krka's 9-mo cons net profit rises 42%

Slovenian drug maker Krka's 9-mo cons net profit rises 42% Source: Krka

LJUBLJANA (Slovenia), November 21 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] said on Thursday its consolidated net profit rose 42% year-on-year in the first nine months of 2019, reaching 171.9 million euro ($190.3 million).

Krka's consolidated sales increased 12% on the year to 1.1 billion euro in the nine months through September, the company said in a filing with the Ljubljana Stock Exchange.

Consolidated revenue increased to 1.09 billion euro in the review period, from 971.6 million euro in January-September 2018.

Krka's consolidated EBITDA amounted to 274.2 million euro at the end of September, up 11% year-on-year.

The Krka Group allocated 81.1 million euro to investments in the first nine months, of which 66.3 million euro to the controlling company.

The group employed 11,481 people at the end of September, up from 11,390 at the end of 2018.

Krka last traded on the Ljubljana Stock Exchange on Wednesday, closing unchanged at 68.8 euro.

($ = 0.90336 euro)

Compare